长期激素治疗对比短期激素治疗在中危前列腺癌患者中的效果:NRG Oncology RTOG 9202 二次分析
该二次分析纳入 RTOG 9202 中 133 例中危前列腺癌患者(74 例短期激素治疗,59 例长期激素治疗),中位随访超过 11 年。结果显示两组在总生存、疾病特异性生存和 PSA 失败率上均无显著差异,长期激素治疗未带来额外获益。
要点
- 中危前列腺癌患者中,长期激素治疗较短期激素治疗未改善总生存(10年 65% vs 61%,P=.53)。
- 疾病特异性生存(10年 97% vs 96%,P=.72)和 PSA 失败率(10年 55% vs 53%,P=.99)两组亦无差异。
- 鉴于缺乏获益且疾病特异性死亡事件少,不建议在中危前列腺癌中探索更长疗程激素治疗。
核心结论
- 在中危前列腺癌亚组中,长期辅助雄激素剥夺治疗未在总生存、疾病特异性生存或 PSA 失败率方面带来获益。
研究设计与样本
- RTOG 9202 随机试验的二次分析,纳入 133 例中危前列腺癌患者(短期激素治疗组 74 例,长期激素治疗组 59 例),中位随访超过 11 年。
主要发现
- 短期激素治疗组 39 例存活,长期激素治疗组 33 例存活。
- 10 年总生存率短期激素治疗组 61%,长期激素治疗组 65%(P=.53)。
- 10 年疾病特异性生存率短期激素治疗组 96%,长期激素治疗组 97%(P=.72)。
- 10 年 PSA 失败率短期激素治疗组 53%,长期激素治疗组 55%(P=.99)。
临床怎么用
- 对于中危前列腺癌患者,在放疗基础上长期辅助激素治疗未显示优于短期激素治疗,不支持常规延长激素治疗疗程。
局限性
- 该亚组样本量相对较小,且观察到的疾病特异性死亡事件数量少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: NRG Oncology RTOG 9202 was a randomized trial testing long-term adjuvant androgen deprivation (LTAD) versus initial androgen deprivation only (STAD) with external beam radiation therapy (RT) in mostly high-risk and some intermediate-risk prostate cancer patients. RTOG 9408 found an overall survival (OS) advantage in patients with cT1b-T2b disease and prostate-specific antigen (PSA) <20 ng/mL, with benefit observed mostly among intermediate-risk patients. It was still unknown whether intermediate-risk patients would experience an additional survival benefit with LTAD; thus, we performed a secondary analysis to explore whether LTAD had any incremental benefit beyond STAD among the intermediate-risk subset of RTOG 9202. The study endpoints were OS, disease-specific survival (DSS), and PSA failure (PSAF). METHODS AND MATERIALS: An analysis was performed for all patients enrolled in RTOG 9202 defined as intermediate-risk (cT2 disease, PSA<10 ng/mL, and Gleason score = 7 or cT2 disease, PSA 10-20 ng/mL, and Gleason score <7). This review yielded 133 patients: 74 (STAD) and 59 (LTAD). The Kaplan-Meier method was used to estimate OS; the cumulative incidence approach was used to estimate DSS and PSAF. A 2-sided test was used, with significance level defined to be .05. RESULTS: With over 11 years of median follow-up, 39 STAD patients were alive and 33 LTAD patients were alive. There was no difference in OS (10-year estimates, 61% STAD vs 65% LTAD; P=.53), DSS (10-year DSS, 96% vs 97%; P=.72), or PSAF (10-year PSAF, 53% vs 55%; P=.99) between groups. CONCLUSION: LTAD did not confer a benefit in terms of OS, DSS, or PSAF rates in the intermediate-risk subset in this study. Whereas the subset was relatively small, treatment assignment was randomly applied, and a trend in favor of LTAD would have been of interest. Given the small number of disease-specific deaths observed and lack of benefit with respect to our endpoints, this secondary analysis does not suggest that exploration of longer hormonal therapy is worth testing in the intermediate-risk prostate cancer subset.
引用
- Mirhadi AJ, Zhang Q, Hanks GE, et al. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2016. PMID: 28126300. doi:10.1016/j.ijrobp.2016.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。